• linkedin
  • Increase Font
  • Sharebar

    Pediatric Pharmacogenomics Offers Treatment Insights

    Think pharmacogenomics is just useful for adults? Think again.


    One drug category of particular concern for pediatric pharmacogenomics is pain relief. One of the seven actionable genes covered in the new testing is CYP2D6, which affects codeine toxicity in children, Hachad said. Antiemetic medications are another drug category where genes affect response or toxicity, she added. In addition to oncology, conditions that can benefit from this testing include sickle cell anemia and behavioral issues such as attention deficit hyperactivity disorder.

    Related article: Study Finds Oral Syringes Better for Liquid Pediatric Meds

    Just as pharmacogenomics testing for adults has moved into community pharmacy, pediatric testing can, too. “A number of retail pharmacies are trying to bring this to patients and clients,” Hachad said. “It is an additional tool to their tool belt to manage complex situations and polypharmacy patients.”

    All patients or their parents must have counseling when they receive any results from pharmacogenomics testing, she added. “The results need to be discussed always with a physician or a pharmacist.”

    Valerie DeBenedette
    Valerie DeBenedette is Managing Editor of Drug Topics.


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available